Pharmaceutical composition for preventing and treating diabetic nephropaphy including adenosine derivative

Abstract

A pharmaceutical composition for preventing or treating diabetic nephropathy is provided. According to the present invention, a pharmaceutical composition for preventing or treating diabetic nephropathy comprises an adenosine derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient.

What is claimed is: 
     
         1 . A method of treating Chronic kidney disease (CKD) in a subject in need thereof, comprising:
 providing a pharmaceutical composition comprising a compound represented by following Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:   
       
         
           
           
               
               
           
         
         wherein, A is O or S, 
         R is i) a linear or branched C 1 -C 5  alkyl which is non-substituted or is substituted with one or more C 6 -C 10  aryl groups; ii) a benzyl which is non-substituted or is substituted with halogen, or one or more linear or branched C 1 -C 4  alkoxy groups; or iii) a hydroxycarbonyl-substituted benzyl, and 
         Y is H or a halogen element; and 
         administering the pharmaceutical composition to the subject, wherein the Chronic kidney disease is treated. 
       
     
     
         2 . The method of  claim 1 , wherein the Chronic kidney disease is diabetic nephropathy. 
     
     
         3 . The method of  claim 2 , wherein the diabetic nephropathy is caused by at least one of type 1 diabetes and type 2 diabetes. 
     
     
         4 . The method of  claim 1 , wherein the compound represented by the Chemical Formula 1 is a compound represented by following Chemical Formula B: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The method of  claim 1 , the pharmaceutical composition is an oral administration agent 
     
     
         6 . The method of  claim 5 , the oral administration agent further comprises an excipient comprising at least one selected from the group consisting of methyl cellulose (MC), dimethyl sulfoxide (DMSO), polyethylene glycol (PEG) and distilled water. 
     
     
         7 . The method of  claim 6 , the oral administration agent comprises 0.5 wt % of methyl cellulose as the excipient. 
     
     
         8 . The method of  claim 5 , wherein the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof is filled in capsules in powder form. 
     
     
         9 . The method of  claim 5 , wherein the compound represented by the Chemical Formula 1 is a compound represented by following Chemical Formula B: